Management of Decompensated Hepatitis B Causing Ascites

Initial Management Approach

The American Association for the Study of Liver Diseases recommends prompt antiviral therapy for patients with decompensated hepatitis B causing ascites, using nucleos(t)ide analogues with high genetic barriers to resistance, such as entecavir or tenofovir, regardless of HBV DNA levels, and liver transplantation should be considered 1, 2, 3
Patients with decompensated cirrhosis should be treated in specialized liver units due to the complexity of management and potential need for liver transplantation, as recommended by the European Association for the Study of the Liver 2, 3
Antiviral treatment is indicated irrespective of HBV DNA level to prevent reactivation, according to the American Association for the Study of Liver Diseases 2
Peginterferon-α is contraindicated in decompensated cirrhosis due to the risk of serious complications, such as hepatic failure, as stated by the American Association for the Study of Liver Diseases 1, 4

The American Association for the Study of Liver Diseases recommends oral nucleos(t)ide analogues (NAs) with high genetic barriers to resistance as the treatment of choice for decompensated hepatitis B causing ascites 1, 5
Monotherapy with either tenofovir or entecavir is preferred as first-line treatment, according to the European Association for the Study of the Liver 1, 2
For entecavir, the recommended dose in decompensated cirrhosis is 1 mg daily, as stated by the European Association for the Study of the Liver 2
Lamivudine should not be used due to high resistance rates, as recommended by the American Association for the Study of Liver Diseases 5, 6

Liver function should be tested every 1-3 months, as recommended by the American Association for the Study of Liver Diseases 1
Serum HBV DNA should be measured by real-time PCR, and HBeAg status should be checked every 2-6 months, according to the American Association for the Study of Liver Diseases 1
Close monitoring of clinical and laboratory parameters is essential, especially in patients with advanced decompensated cirrhosis, due to the risk of lactic acidosis, as stated by the European Association for the Study of the Liver 2
Monitor for hepatitis flares which may occur during treatment and require urgent management, as recommended by the European Association for the Study of the Liver 2

Clinical improvement often requires 3-6 months of antiviral therapy, as stated by the American Association for the Study of Liver Diseases 1, 2
Patients may show slow clinical improvement over a period of 3-6 months under NA therapy, potentially avoiding the need for transplantation, according to the European Association for the Study of the Liver 2
Prolonged and adequate suppression of HBV DNA can stabilize patients and prevent progression of decompensated liver disease, as recommended by the European Association for the Study of the Liver 2
Some patients with advanced hepatic disease with high Child-Pugh or MELD scores may have progressed beyond the point of no return and may still require liver transplantation despite antiviral therapy, as stated by the European Association for the Study of the Liver 2

Liver transplantation should be considered for patients with decompensated HBV cirrhosis, as recommended by the American Association for the Study of Liver Diseases 1, 4
Pre-transplant therapy with potent NAs with high barriers to resistance is recommended to achieve the lowest possible HBV DNA level before transplantation, according to the European Association for the Study of the Liver 2
Treatment with NAs inducing HBV DNA undetectability at transplantation will decrease the risk of HBV recurrence in the graft, as stated by the European Association for the Study of the Liver 2

Antiviral therapy should typically be continued indefinitely (lifelong) in patients with decompensated cirrhosis, as recommended by the European Association for the Study of the Liver 2, 6
Treatment discontinuation is generally not recommended unless HBsAg loss and anti-HBs seroconversion is achieved and maintained for 6-12 months, as stated by the European Association for the Study of the Liver 2